Andere Sprachen Orgenesis Inc.

Aktien

A2H7XQ

US68619K2042

ORGS

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:05:13 25.04.2024			% 5 Tage	% 1. Jan.
0,511 ^USD	+1,79 %		-2,34 %	-0,12 %

15.04.	Orgenesis Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
10.04.	Germfree und Orgenesis Inc. kündigen den Kauf von Vermögenswerten und eine strategische Partnerschaft an, um die Zell- und Gentherapie durch dezentrale Produktion und globale Zugänglichkeit zu revolutionieren	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Powell Comments, -2-	16.04.
Orgenesis Provides Year End Business Update	15.04.
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15.04.
Orgenesis : Non-Reliance on Previously Issued Financial Report - Form 8-K	15.04.
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	10.04.
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	10.04.
North American Morning Briefing : Stocks Seen -2-	02.04.
North American Morning Briefing : Markets Steady -2-	26.03.
North American Morning Briefing : Stock Futures -2-	19.03.
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference	18.03.
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes	13.03.
Orgenesis Inc. announced that it has received $2.340901 million in funding	05.03.
Orgenesis Inc. Announces $2.3 Million Private Placement	04.03.
Orgenesis Inc. announced that it expects to receive $2.340901 million in funding	03.03.
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing	29.02.
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic	31.01.
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.	31.01.
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.	24.01.
Alimera Sciences Appoints New CFO	02.01.
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM	14.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Orgenesis Inc.

Aktien

A2H7XQ

US68619K2042

ORGS

Andere Sprachen

Filter